Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

Citation metadata

Authors: Claude Preudhomme, Joelle Guilhot, Franck Emmanuel Nicolini, Agnes Guerci-Bresler, Francoise Rigal-Huguet and Virginie Eclache
Date: Dec. 23, 2010
From: The New England Journal of Medicine(Vol. 363, Issue 26)
Publisher: Massachusetts Medical Society
Document Type: Clinical report
Length: 40 words

Document controls

Format Options:
Translate Article
Set Interface Language
Colors:
Font:
Open SansEB GaramondOpen DyslexicNoto Sans
DefaultMoreMost
Line Spacing
Letter Spacing
Word Spacing

Main content

Abstract :

A study was conducted to evaluate the efficacy of Imatinib plus peginterferon alfa-2a in the treatment of chronic myeloid leukemia (CML). Results indicated that such a form of treatment resulted in significantly higher rates of molecular response in such patients.

Source Citation

Source Citation   

Gale Document Number: GALE|A247663156